Overview

Phase I/II, Open-label Dose-Escalation Randomized Study of High-Dose mRNA-1273 Booster for Lung Transplant Recipients

Status:
Not yet recruiting

Trial end date:
2025-03-10

Target enrollment:

Participant gender:

Summary

Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes. This is a Phase I/II clinical trial to evaluate the safety and immune response from a higher dose mRNA-1273 vaccine among lung transplant recipients who have already received three doses of the COVID-19 vaccine.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of California, Los Angeles

Collaborator:

ModernaTX, Inc.